We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Dipstick Rapidly Detects Cholera in Acute Diarrhea

By LabMedica International staff writers
Posted on 29 Mar 2018
Cholera is an acute watery diarrheal disease caused mainly by Vibrio cholerae serogroup O1 and less commonly by V. More...
cholerae O139. Cholera can lead to severe diarrhea and death if untreated.

Recognizing cholera cases early, especially in the initial phase of an outbreak and in areas where cholera has not previously circulated, is a high public health priority and laboratory capacity in such settings is often limited. Globally, 3 to 5 million cases and over 100,000 deaths occur annually due to cholera.

An international team of scientists working with the International Centre for Diarrhoeal Disease Research (Dhaka, Bangladesh) collected fresh stools from 76 hospitalized adults and children at the Dhaka Hospital who presented with acute watery diarrhea. They performed conventional stool culture by streaking stool directly on selective TTGA (taurocholate-tellurite gelatin agar) plates, and incubated these plates overnight at 37 °C.

Colonies morphologically consistent with V. cholerae were analyzed by slide agglutination with monoclonal antibodies specific to V. cholerae serovar O1 (Ogawa or Inaba) and O139. The team compared their recently developed rapid diagnostic test (RDT) termed Cholkit that is based on an immunochromatographic lateral flow assay for the diagnosis of cholera cases using stool with the commercially available RDT, Crystal VC and a polymerase chain reaction (PCR) targeting the rfb and ctxA genes of V. cholerae.

The scientists reported that stool specimens from 76 patients were tested by all four of microbial culture, Cholkit, Crystal VC and PCR assays. Nineteen samples were positive by culture and all of them were confirmed as positive for V. cholerae O1 Inaba except one sample that was V. cholerae O1 Ogawa. Out of 19 stools positive by culture, all 19 (100%) were positive by both Cholkit and Crystal VC assays, and 15 (79%) were positive by PCR. Of all of the 57 patients with a negative stool culture Cholkit, Crystal VC and PCR were positive for 11 (19%), 12 (21%), and 6 (11%), respectively.

The authors concluded that the Cholkit dipstick is simple to use, requires no dedicated laboratory capacity, and has a sensitivity and specificity for V. cholerae O1 of 98% and 97%, respectively. The study was published on March 14, 2018, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
International Centre for Diarrhoeal Disease Research


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Manual Pipetting Aid
Pipette Controllers macro
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: GRAIL’s Galleri test uses machine learning to analyze cfDNA patterns for cancer signals and predict their likely location to guide further evaluation.

Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options

Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.